Platelets are key mediators in the pathophysiology of atherothrombotic disease. Inappropriate platelet activation can lead to thrombosis and ischemic events. Platelet function testing has been used to monitor patient response to antiplatelet therapy. Variability in response to antiplatelet therapy may be due in part to incomplete inhibition of targeted pathways (thromboxane A2 and adenosine diphosphate [ADP]) by currently available agents (aspirin and P2Y12 ADP receptor antagonists). Low responsiveness to antiplatelet therapy (as measured in various platelet function assays) correlates with a high rate of ischemic events. However, tailoring treatment based on platelet response remains to be definitively proven in clinical trials, correlations between assays are modest, and concordance in defining suboptimal response is poor. Additional studies are needed to determine whether changes in therapy based on results of platelet function testing improve clinical outcomes, and thus will determine whether broader use of platelet function testing in clinical practice is warranted.
Brass LFThrombin and platelet activation. Chest. 2003 ;124(3 suppl):18S-25S.
2.
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med.2007;357(24):2482-2494.
3.
Offermanns S.Activation of platelet function through G protein-coupled receptors. Circ Res. 2006;99(12): 1293-1304.
4.
Varga-Szabo D., Pleines I., Nieswandt B.Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28(3):403-412.
5.
Braunwald E. , Angiolillo D., Bates E., et al. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008;31(3 suppl 1):136.
6.
Michelson ADPlatelet function testing in cardiovascular diseases. Circulation. 2004;110(19):e489-e493.
7.
Angiolillo DJ , Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives . J Am Coll Cardiol. 2007;49(14):1505-1516.
8.
Ruggeri ZMPlatelets in atherothrombosis. Nat Med. 2002 ;8(11):1227-1234.
9.
Furie B., Furie BCMechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-949.
10.
Steinhubl SR , Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-2420.
11.
Michelson AD , Cattaneo M., Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost . 2005;3(6): 1309-1311.
12.
Blindt R., Stellbrink K., de Taeye A., et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost. 2007;98(6):1329-1334.
13.
Campbell CL , Smyth S., Montalescot G., Steinhubl SRAspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18):2018-2024.
14.
Gum PA, Kottke-Marchant K., Welsh PA, White J., Topol EJA prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41(6):961-965.
15.
Gurbel PA, Bliden KP, DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115(25):3156-3164.
16.
Eikelboom JW , Hirsh J., Weitz JI, Johnston M., Yi Q., Yusuf S.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation . 2002;105:1650-1655.
17.
Schwartz KA , Schwartz DE, Ghosheh K., Reeves MJ, Barber K., DeFranco A.Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005;95(8):973-975.
18.
Fontana P., Nolli S., Reber G., de Moerloose P.Biological effects of aspirin and clopidogrel in a randomized crossover study in 96 healthy volunteers. J Thromb Haemost. 2006;4(4):813-819.
19.
Montalescot G.Prevalence and clinical impact of upper gastrointestinal symptoms in patients treated with low-dose aspirin. In: European Society of Cardiology Congress; August 30-September 3, 2008; Munich, Germany. Abstract P3676.
20.
Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48(5):931-938.
21.
Collet JP, Silvain J., Landivier A., et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study . Circulation. 2008;118(12):1225-1233.
22.
L’Allier PL, Ducrocq G., Pranno N., et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J Am Coll Cardiol. 2008;51(11):1066-1072.
23.
Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006;48(7):1339-1345.
24.
Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation . 2005;111(20):2560-2564.
25.
Matetzky S. , Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171-3175.
26.
Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol.2008;51(14):1404-1411.
27.
Angiolillo DJ, Bernardo E., Palazuelos J., et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions . Results of a randomized study. Thromb Haemost. 2008;99(1):161-168.
28.
Aleil B., Jacquemin L., De Poli F., et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Int. 2008;1(6):631.
29.
Lemesle G., Delhaye C., Sudre A., et al. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome . Am Heart J. 2009;157(2):375-382.
30.
Marcucci R. , Gori AM, Paniccia R., et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis . 2007;195(1):e217-e223.
31.
Bliden KP, Dichiara J., Lawal L., et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol. 2008;52(7):531-533.
32.
Zevin S., Benowitz NLDrug interactions with tobacco smoking. An update. Clin Pharmacokinet . 1999;36(6): 425-438.
33.
Wiviott SD, Braunwald E., McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
34.
Montalescot G., Wiviott SD, Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373 (9665):723-731.
35.
Jernberg T. , Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166-1173.
36.
Wallentin L. , Varenhorst C., James S., et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29(1):21-30.
37.
Frelinger AL , Michelson AD, Braunwald E., et al. Abstract 3994: Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 trial. Circulation. 2008;118(suppl 18):S814.
38.
Cattaneo M.P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J. 2006;27(9):1010-1012.
39.
Husted S., Emanuelsson H., Heptinstall S., Sandset PM, Wickens M., Peters G.Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038-1047.
40.
Storey RF, Husted S., Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852-1856.
41.
Storey RF, Wilcox RG, Heptinstall S.Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13(7): 407-413.
42.
Montalescot G., Bal-dit-Sollier C., Chibedi D., et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol. 2003;91(8):925-930.
43.
Steinhubl SR , Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001;103(21):2572-2578.
44.
Kini AS, Richard M., Suleman J., et al. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardiol. 2002;90(5): 526-529.
45.
Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry USClopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111(9):1153-1159.
46.
Gurbel PA, Bliden KP, Saucedo JF, et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study . J Am Coll Cardiol. 2009;53(8):648-657.
47.
Smith SC Jr , Feldman TE, Hirshfeld JW Jr, et al. ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113(1):156-175.
48.
Collet JP, Hulot JS, Pena A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317.
49.
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med.2009;360(4):354-362.
50.
Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med. 2009;360(4):363-375.
51.
Trenk D., Hochholzer W., Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents . J Am Coll Cardiol. 2008;51(20):1925-1934.
52.
Montalescot G.Prasugrel 10 mg provides greater platelet inhibition than clopidogrel 900/150 mg in UA/ NSTEMI ACS - The ACAPULCO study. In: European Society of Cardiology Congress; August 30-September 3, 2008; Munich, Germany. Abstract 4408.
